Disease · MONDO_0700081
newborn respiratory distress syndrome
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. newborn respiratory distress syndrome. Diseases, record MONDO_0700081. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0700081
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
HMD - Hyaline membrane disease, RDS Of newborns, RDS, respiratory distress syndrome Of newborns, hyaline membrane disease, infant ARDS, infant acute respiratory distress syndrome, infant respiratory distress syndrome, neonatal respiratory distress, neonatal respiratory distress syndrome, newborns (RDS), respiratory distress syndrome Of, pulmonary hyaline membrane disease, pulmonary hypoperfusion syndrome of newborn, respiratory distress syndrome Of newborns, respiratory distress syndrome Of newborns (RDS), respiratory distress syndrome in the newborn, respiratory distress syndrome of newborn, syndrome Of newborns (RDS), respiratory distress
- Open Targets
Drugs24
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PORACTANT ALFA | CHEMBL1201622 | Approval | DailyMed and TTD | 27 | 25 | 10 | Drugs and targets | |
| BERACTANT | CHEMBL1201624 | Approval | DailyMed and TTD | 22 | 20 | 4 | Drugs and targets | |
| CALFACTANT | CHEMBL1201447 | Approval | DailyMed | 6 | 5 | 5 | Drugs and targets | |
| LUCINACTANT | CHEMBL1963685 | Approval | TTD | 3 | 2 | 1 | Drugs and targets | |
| COLFOSCERIL PALMITATE | CHEMBL1200737 | Small molecule | Approval | DailyMed and TTD | 4 | 1 | 0 | Drugs and targets |
| PICROTOXIN | CHEMBL1908342 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| INDOMETHACIN | CHEMBL6 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| KETAMINE | CHEMBL742 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NITRIC OXIDE | CHEMBL1200689 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PROPOFOL | CHEMBL526 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 24
See all 24 drugsTargets30
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 3 | Glucocorticoid receptor agonist | Phase 2 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 2 | Cyclooxygenase inhibitor | Phase 3 | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 2 | Cyclooxygenase inhibitor | Phase 3 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| GABRA1 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2555 | Drugs and targets |
| GABRA3 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2556 | Drugs and targets |
| GABRA4 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2557 | Drugs and targets |
| GABRA5 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2558 | Drugs and targets |
| GABRA6 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2559 | Drugs and targets |
| GABRB1 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2560 | Drugs and targets |
1 to 10 of 30
See all 30 targetsTrials29
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 16 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03058666 | Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients | Phase 3 | 477 | 2024-05-29 | Respiratory Distress Syndrome | CALFACTANT | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03969992 | A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact | Phase 2 | 261 | 2025-08-07 | Respiratory Distress Syndrome in Premature Infant | CALFACTANT | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02452476 | A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC) | Phase 2 | 123 | 2021-06-23 | Respiratory Distress Syndrome, Newborn | PORACTANT ALFA | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02772081 | A Study in Preterm Neonates With Respiratory Distress Syndrome (RDS) Comparing CUROSURF® Administration Through Less Invasive Surfactant Administration (LISA) and Conventional Administration | Phase 3 | 33 | 2023-11-03 | Respiratory Distress Syndrome (RDS) | PORACTANT ALFA | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02834624 | Comparison of Curosurf and Infasurf in the Treatment of Preterm Infants With Respiratory Distress Syndrome | Not applicable | 30 | 2017-06-06 | Respiratory Distress Syndrome | CALFACTANT, PORACTANT ALFA | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04264156 | A Safety and Efficacy Study of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age | Phase 2 | 12 | 2023-05-24 | Respiratory Distress Syndrome, Newborn | LUCINACTANT | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01203358 | Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome | Phase 2/3 | 617 | Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Bronchopulmonary Dysplasia | BERACTANT | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT05609877 | The NONA-LISA Trial | Not applicable | 324 | Respiratory Distress Syndrome in Premature Infant | FENTANYL, SODIUM CHLORIDE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT02013115 | Curosurf/Budesonide for Infants With Respiratory Distress Syndrome | Not applicable | 300 | Respiratory Distress Syndrome | BUDESONIDE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT04016246 | Respiratory Effect of the LISA Method With Sedation by Propofol Versus Absence of Sedation. | Phase 3 | 233 | Respiratory Distress Syndrome in Premature Infant | KETAMINE, PROPOFOL | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 29
See all 29 trialsComparisons in its trials20
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Aerosolized Calfactant vs Usual Care: Air Leak | 14 of 241 | 11 of 236 | 477 | NCT03058666 | Trial comparisons |
| Aerosolized Calfactant vs Usual Care: deaths from any cause | 0 of 241 | 1 of 236 | 477 | NCT03058666 | Trial comparisons |
| Aerosolized Calfactant vs Usual Care: Intubation and Instillation of Liquid Surfactant | 69 of 241 | 120 of 236 | 477 | NCT03058666 | Trial comparisons |
| Aerosolized Calfactant vs Usual Care: Respiratory Support Requirements | 65 of 241 | 124 of 236 | 477 | NCT03058666 | Trial comparisons |
| Aerosolized Calfactant vs Usual Care: serious adverse events | 13 of 241 | 14 of 236 | 477 | NCT03058666 | Trial comparisons |
| CHF5633 vs Poractant Alfa: deaths from any cause | 4 of 59 | 7 of 58 | 117 | NCT02452476 | Trial comparisons |
| CHF5633 vs Poractant Alfa: serious adverse events | 20 of 59 | 20 of 58 | 117 | NCT02452476 | Trial comparisons |
| CHF5633 vs Poractant Alfa: Number of Patients With Normal Breathing (Room Air) Within 24 Hours | 38 of 56 | 43 of 57 | 113 | NCT02452476 | Trial comparisons |
| Curosurf LISA vs Curosurf Endotracheal Tube: Efficacy: Neonates Needing Additional Surfactant Doses | 6 of 19 | 3 of 12 | 31 | NCT02772081 | Trial comparisons |
| Curosurf LISA vs Curosurf Endotracheal Tube: deaths from any cause | 1 of 19 | 1 of 12 | 31 | NCT02772081 | Trial comparisons |
1 to 10 of 20
See all 20 comparisons in its trialsPapers from its trials55
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0700081
GET https://conductscience.org/api/diseases/v1/MONDO_0700081/drugs?page=2